GLP-1 Drug Prices & Medicare Coverage
Ozempic, Wegovy, Mounjaro, Zepbound, and Rybelsus — NADAC acquisition costs and Medicare Part D status. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Pricing data from CMS NADAC, effective December 18, 2024. Source: CMS Pharmacy Pricing.
GLP-1 Drug Comparison
NADAC pharmacist acquisition costs at starting dose. Patient out-of-pocket cost varies by insurance and manufacturer savings programs.
Monthly estimates based on typical starting-dose volumes. NADAC = pharmacist acquisition cost, not retail price.
Drug Profiles
Semaglutide
Novo Nordisk — Brand names: Ozempic, Wegovy, Rybelsus
Semaglutide is a GLP-1 receptor agonist approved for Type 2 diabetes (Ozempic, Rybelsus) and chronic weight management (Wegovy). It stimulates insulin release, suppresses glucagon secretion, and slows gastric emptying. The SUSTAIN trials (Ozempic) and SELECT trial (Wegovy) demonstrated significant cardiovascular benefits in patients with established CVD.
Ozempic
$311.86/ML
~$935.58/mo
Diabetes (Type 2)Wegovy
$650.47/ML
~$1300.93/mo
Weight LossRybelsus
$31.15/EA
~$934.39/mo
Diabetes (Type 2)Show all 17 NADAC records for semaglutide
| NDC Description | NADAC/Unit | Unit | Type |
|---|---|---|---|
| RYBELSUS 3 MG TABLET | $31.15 | EA | Brand |
| RYBELSUS 3 MG TABLET | $31.15 | EA | Brand |
| RYBELSUS 14 MG TABLET | $31.16 | EA | Brand |
| RYBELSUS 14 MG TABLET | $31.16 | EA | Brand |
| RYBELSUS 7 MG TABLET | $31.16 | EA | Brand |
| RYBELSUS 7 MG TABLET | $31.16 | EA | Brand |
| OZEMPIC 2 MG/DOSE (8 MG/3 ML) PEN | $311.79 | ML | Brand |
| OZEMPIC 2 MG/DOSE (8 MG/3 ML) PEN | $311.79 | ML | Brand |
| OZEMPIC 1 MG/DOSE (4 MG/3 ML) PEN | $311.85 | ML | Brand |
| OZEMPIC 1 MG/DOSE (4 MG/3 ML) PEN | $311.85 | ML | Brand |
| OZEMPIC 0.25-0.5 MG/DOSE (2 MG/3 ML) PEN | $311.86 | ML | Brand |
| OZEMPIC 0.25-0.5 MG/DOSE (2 MG/3 ML) PEN | $311.86 | ML | Brand |
| WEGOVY 1.7 MG/0.75 ML PEN | $433.53 | ML | Brand |
| WEGOVY 2.4 MG/0.75 ML PEN | $433.73 | ML | Brand |
| WEGOVY 1 MG/0.5 ML PEN | $650.14 | ML | Brand |
| WEGOVY 0.25 MG/0.5 ML PEN | $650.47 | ML | Brand |
| WEGOVY 0.5 MG/0.5 ML PEN | $650.50 | ML | Brand |
Tirzepatide
Eli Lilly — Brand names: Mounjaro, Zepbound
Tirzepatide is a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor agonist. By targeting two incretin pathways, it produces greater reductions in HbA1c and body weight compared to GLP-1-only agents. The SURPASS trials demonstrated superior glycemic control for Mounjaro, while the SURMOUNT trials demonstrated 20–22% average weight loss for Zepbound.
Mounjaro
$515.90/ML
~$1031.81/mo
Diabetes (Type 2)Zepbound
$511.12/ML
~$1022.24/mo
Weight LossShow all 12 NADAC records for tirzepatide
| NDC Description | NADAC/Unit | Unit | Type |
|---|---|---|---|
| ZEPBOUND 7.5 MG/0.5 ML PEN | $510.89 | ML | Brand |
| ZEPBOUND 15 MG/0.5 ML PEN | $510.92 | ML | Brand |
| ZEPBOUND 5 MG/0.5 ML PEN | $510.97 | ML | Brand |
| ZEPBOUND 12.5 MG/0.5 ML PEN | $511.01 | ML | Brand |
| ZEPBOUND 10 MG/0.5 ML PEN | $511.06 | ML | Brand |
| ZEPBOUND 2.5 MG/0.5 ML PEN | $511.12 | ML | Brand |
| MOUNJARO 15 MG/0.5 ML PEN | $515.58 | ML | Brand |
| MOUNJARO 12.5 MG/0.5 ML PEN | $515.75 | ML | Brand |
| MOUNJARO 10 MG/0.5 ML PEN | $515.85 | ML | Brand |
| MOUNJARO 2.5 MG/0.5 ML PEN | $515.90 | ML | Brand |
| MOUNJARO 5 MG/0.5 ML PEN | $515.95 | ML | Brand |
| MOUNJARO 7.5 MG/0.5 ML PEN | $515.96 | ML | Brand |
Medicare Part D Coverage
| Drug | Indication | Part D Coverage |
|---|---|---|
| Ozempic | Type 2 Diabetes | Covered |
| Wegovy | Weight Loss | Covered (Part D, 2026) |
| Rybelsus | Type 2 Diabetes | Covered |
| Mounjaro | Type 2 Diabetes | Covered |
| Zepbound | Weight Loss | Limited |
Coverage reflects CMS policy as of early 2025. Individual Part D plan formularies vary. Use the Medicare Plan Finder to check your specific plan.
Frequently Asked Questions
What are GLP-1 receptor agonists?
GLP-1 (glucagon-like peptide-1) receptor agonists are a class of medications that mimic the GLP-1 hormone, which stimulates insulin release after eating. Originally approved for Type 2 diabetes, several GLP-1 drugs have since received FDA approval for chronic weight management.
What is the difference between Ozempic and Wegovy?
Both Ozempic and Wegovy contain semaglutide (manufactured by Novo Nordisk), but they are FDA-approved for different conditions. Ozempic is approved for Type 2 diabetes management, while Wegovy is approved for chronic weight management in adults with obesity or overweight with a weight-related condition. Wegovy is available in higher doses (up to 2.4 mg) than Ozempic (up to 2 mg).
What is the difference between Mounjaro and Zepbound?
Mounjaro and Zepbound both contain tirzepatide (manufactured by Eli Lilly), but are FDA-approved for different conditions. Mounjaro is approved for Type 2 diabetes, while Zepbound is approved for chronic weight management. Tirzepatide is a dual GIP/GLP-1 receptor agonist, targeting two incretin hormone pathways.
Does Medicare cover GLP-1 drugs for weight loss?
Medicare Part D covers GLP-1 drugs when prescribed for Type 2 diabetes (Ozempic, Mounjaro, Rybelsus). Starting January 2026, Medicare Part D plans may cover Wegovy for obesity treatment in patients with established cardiovascular disease. Zepbound coverage under Medicare remains limited. Coverage varies by plan — verify with your insurer.
What does NADAC pricing mean?
NADAC (National Average Drug Acquisition Cost) is the average price pharmacies pay to acquire medications, published weekly by the Centers for Medicare & Medicaid Services (CMS). It represents wholesale acquisition cost — not what patients pay at the counter. Actual patient costs depend on insurance, rebates, manufacturer coupons, and pharmacy markups.
Are there generics available for GLP-1 drugs?
No FDA-approved generic versions of semaglutide or tirzepatide are currently available (as of early 2025). Novo Nordisk patents on semaglutide are expected to expire in the early 2030s. The FDA has warned against compounded versions from unlicensed sources, which lack the safety and efficacy guarantees of FDA-approved products.
How are monthly cost estimates calculated?
Monthly cost estimates are computed from NADAC per-unit prices multiplied by typical starting-dose monthly volumes. Ozempic: one 3 mL pen per month. Wegovy: one 0.5 mL injection per week (approx 2 mL/mo). Rybelsus: 30 tablets per month. Mounjaro/Zepbound: one 0.5 mL injection per week (approx 2 mL/mo). These are pharmacist acquisition costs — patient out-of-pocket costs will differ.
Related Pages
Semaglutide
FDA safety data, side effects & interactions
Tirzepatide
FDA safety data, side effects & interactions
Drug Pricing Hub
Compare NADAC costs across all drugs
Brand vs Generic Guide
When generics are available and equivalent
Drug Shortages
FDA-reported current drug shortages
Drug Compare Tool
Side-by-side comparison of any two drugs
Data Sources: Pricing from CMS NADAC. Medicare coverage from CMS.gov. FDA approval from FDA Drug Database.